Condition: Ovarian Cancer · Sponsor: Persevere Therapeutics Inc.
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy completed enrolment.
This description comes directly from the study's public registry record.
Kathryn M Martin, PharmD · 8455481808 · kmmartin@glenmereresearch.com
Seymour Fein, MD · 610-922-1910 · seymour.fein@perseveretherapeutics.com
Always discuss trial participation with your own doctor first.
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Abramson Cancer Center at the University of Pennsylvania | Phildelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03854110